drugset / Trial / NCT07593170

AKK Study in Improving Obesity and Metabolic Status in Children and Adolescents

NCT07593170 ↗

Phase 2 Not yet recruiting 100 enrolled Central South University Hunan Children's Hospital · collab
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The problem of obesity among children and adolescents is becoming increasingly serious and may affect their health in adulthood. Researches have found that a type of probiotic in the intestinal tract - "Akkermansia muciniphila" (referred to as AKK), may help regulate metabolism and weight. Although it has shown effects in adults, its safety and efficacy in children and adolescents still need further verification. This study aims to evaluate the effects of supplementing Akkermansia Muciniphila AKK PROBIO on weight, metabolic health and intestinal flora of obese children and adolescents aged 7 to 18.

Timeline

Start
2026-06-06
Primary completion
2026-12-20
Completion
2027-02-12

Drugs

EvaluationDrugModalityDoseRoute
Subject AKK PROBIO Other / unclassified 3e+10 cells Oral

Indications